Related Experiment Video
Updated: Sep 15, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Multivessel Coronary Artery Disease in a Patient Treated With Tofacitinib: A Case Report
Wongelawit Zerihun1, Joud Fahed1, Danhue Moodie1
1Department of Internal Medicine, Ascension Saint Agnes Hospital, Baltimore, USA.
None:
Tofacitinib is a second-generation selective Janus kinase (JAK) inhibitor targeting the JAK1 enzyme, which is used to treat several autoimmune diseases, including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, idiopathic arthritis, and ulcerative colitis. JAKs are enzymes that play a key role in inflammatory and immune signaling pathways. The medication is particularly useful as it can be given orally. However, over time, there has been much data that links this drug with an increased risk of cardiovascular events. We present a case of a 73-year-old male with a history of RA and hypertension presenting to the hospital with typical cardiac chest pain. He was found to have ischemic EKG changes and elevated troponin levels. He then underwent cardiac catheterization, which revealed significant coronary artery disease.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Coronary Artery Disease III: Clinical Manifestations
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myocarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

